Search Results for "Harvoni"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Harvoni. Results 11 to 14 of 14 total matches.
See also: ledipasvir, sofosbuvir
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
for dabigatran
Ledipasvir/sofosbuvir (Harvoni, and authorized generic)
P-gp inducers2 Decreased DAA serum ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175 doi:10.58347/tml.2024.1714f | Show Introduction Hide Introduction
Prescription Drug Prices in the US
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
/sofosbuvir – Harvoni (Gilead) 31,500.008 23,561.708
Rosuvastatin9 – Crestor (AstraZeneca) 260.90 55.30 ...
Per capita spending on prescription drugs in the US is
higher than in other industrialized nations, including
Canada.
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Aug 15, 2016 (Issue 1501)
Harvoni (Gilead) 90/400 mg ledipasvir/ 1 tab once/d x 12 wks3,5 1, 4, 5, 6 14 94,500
sofosbuvir tabs ...
The FDA has approved Epclusa (Gilead), a fixed-dose
combination of sofosbuvir (Sovaldi) and velpatasvir,
a new direct-acting antiviral agent, for oral treatment
of chronic hepatitis C virus (HCV) infection. Epclusa
is the first oral combination to be approved for
treatment of all six major HCV genotypes.
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
for DAA-Experienced Patients1
Previously
Regimen Failed DAA2 Genotype
Ledipasvir/sofosbuvir (Harvoni ...
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of the
six major HCV genotypes in patients without cirrhosis
or with compensated cirrhosis. Both are approved for
use in treatment-experienced patients. Mavyret is also
approved for treatment-naive patients.